This is a multicenter clinical trial with randomized treatment allocation, open label treatment and blinded endpoint evaluation (PROBE design).

The intervention contrast is endovascular treatment versus no endovascular treatment.
The treatment is provided in addition to best medical management.

Patients with AIS, ICH ruled out with non-contrast CT, a confirmed intracranial anterior circulation occlusion and poor to good collaterals on CTA will be included. Treatment should be started between 6 and 24 hours after symptom onset. Age should be 18 or over and NIHSS 2 or more.

The primary outcome is the score on the modified Rankin Scale at 90 days after inclusion.